Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

vutrisiran sodium

AMVUTTRA

vutrisiran sodium (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 13
Pipeline programs 1
News articles 1
Drug details — vutrisiran sodium
US status
approved
Class
—
Route
SUBCUTANEOUS
Patents
13
Programs
1
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

vutrisiran sodium (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN vutrisiran sodium
Brand AMVUTTRA
Mechanism Transthyretin mRNA rnai inhibitor
Target Transthyretin mRNA
Route SUBCUTANEOUS
Formulation SOLUTION
Originator Alnylam Netherlands B.V.

Mechanism of action

Transthyretin mRNA rnai inhibitor

Primary target: Transthyretin mRNA

Approval history

Authority Status Date
FDA approved —

Recent coverage

View all news
Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability
High impact NewsATTR-CMJun 8, 2026

Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability

U.S. FDA · ATTR-CM · 5 min

Alnylam pipeline momentum is anchored by AMVUTTRA’s FDA-approved ATTR-CM and hATTR-PN uses, plus two active Phase 3 catalysts. The update focuses on what changed, what it means for investors, and what to watch next.

Dr. Sarah Mitchell

Pipeline programs

Search pipeline Sponsor programs
  1. Vutrisiran Phase 3 · Alnylam Netherlands · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Related & competitor drugs

Browse all drugs
  1. patisiran Nervous system (N07)
  2. patisiran sodium Transthyretin mRNA RNAi inhibitor
  3. vutrisiran Nervous system (N07)
  4. eplontersen sodium Transthyretin mRNA antisense inhibitor
  5. inotersen sodium Transthyretin mRNA antisense inhibitor
  6. eplontersen Nervous system (N07)

Related patents

Browse patents Alnylam Netherlands B.V. patent hub

  1. US 12049628

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11401517

    Modified double-stranded RNA agents

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11286486

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10806791

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10683501

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10612024

    Modified double-stranded RNA agents

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10570391

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10208307

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10131907

    Glycoconjugates of RNA interference agents

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9399775

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9370581

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8828956

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8106022

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is vutrisiran sodium?

vutrisiran sodium (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for vutrisiran sodium?

AMVUTTRA is a marketed brand name for vutrisiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vutrisiran sodium?

vutrisiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.